Phase IIb Study of Dapagliflozin and Baxdrostat for Chronic Kidney Disease and High Blood Pressure
This study is testing if combining two medications, dapagliflozin and baxdrostat, is better than baxdrostat alone at reducing albuminuria (a sign of kidney damage) in people with chronic kidney disease and high blood pressure. We are looking for adults aged 18 and older with specific kidney function (eGFR between 30 and 90 mL/min/1.73 m2) and albumin levels (UACR between 200 and 5000 mg/g). The main goal is to see if the combination treatment significantly lowers albuminuria within 12 weeks. The study is currently unclear on its recruitment status.
- Study design
- This is a Phase IIb, international, multicenter, double-blind, randomized study aiming to enroll 218 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome is measured at up to 12 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
At a glance
Conditions
Where it's being run
71 sites across 23 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To determine whether baxdrostat/dapagliflozin is superior to baxdrostat/matching placebo at reducing albuminuria.Up to 12 weeks
Change from baseline in UACR